Friday, June 13, 2025

Latest

The Solution To Antibiotic Resistance – With Cytophage CEO Dr Steven Theriault

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.

In this interview, Dr. Steven Theriault BSc, MSc, PhD, CEO of Cytophage Technologies Ltd (TSXV: CYTO), sits down with Small Cap Steve to shed light on Cytophage’s groundbreaking work in health science, specifically addressing bacterial infections through tailored bacteriophages. Bacteriophages, viruses that selectively infect and eliminate bacteria, offer an eco-friendly alternative to antibiotics.

Dr. Theriault emphasizes the pressing issue of antibiotic resistance and the critical need for innovative solutions. Cytophage’s technology, spanning human health, animal well-being, and food safety, presents a comprehensive approach. The interview explores the company’s mission to commercialize products globally, potentially revolutionizing bacterial infection treatments on a worldwide scale.


FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Aznalcóllar Corruption Case Nears Conclusion | David Gower – Emerita Resources

Why Precious Metals Crashed on Trump’s Trade Deals? | Jesse Day

Big Gold Miners Don’t Trust $3,300 Gold, Do They See a Crash Ahead? | Rob McEwen

Recommended

NexGen Energy Receives Approval For Site Expansion At Rook I Project

ESGold Sees Installation Of Humphrey Spirals Completed At Montauban

Related News

Cytophage Enters Partnership To Launch Phage Clinical Treatment Program In Manitoba

Cytophage Technologies (TSXV: CYTO) announced a landmark agreement this morning that will see the establishment...
Thursday, December 12, 2024, 05:14:00 PM

Cytophage To Focus On Commercialization Efforts In 2024

Cytophage Technologies (TSXV: CYTO) has filed its fiscal 2023 results, providing a recap on a...
Tuesday, April 30, 2024, 10:13:02 AM

Cytophage Adds 30-Year Biotech Exec To Its Board

Cytophage Technologies (TSXV: CYTO) has added bench strength to its board of directors this morning,...
Monday, May 27, 2024, 09:09:36 AM

Phage Therapy’s Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault

In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy...
Thursday, August 15, 2024, 02:04:00 PM

Cytophage Develops Freeze-Dried Phage Tablets For Poultry

Cytophage Technologies (TSXV: CYTO) has announced the launch of a new product that it believes...
Thursday, August 15, 2024, 02:56:00 PM